

Supplementary tables

Table S1. Clinicopathological characteristics of the subgroups based on ER pathway activity in postmenopausal HGSC patients.

Variable	Quartile 1 <i>n</i> =17 (%)	Quartile 2 <i>n</i> =17 (%)	Quartile 3 <i>n</i> =17 (%)	Quartile 4 <i>n</i> =16 (%)	P-value*
Age at diagnosis					0.828
Median (IQR)	65 (63 – 72)	65 (61 – 71)	67 (59 – 73)	64 (58 – 72)	
FIGO stage					1.000
IIIC	15 (88)	15 (88)	15 (88)	14 (87)	
IV	2 (12)	2 (12)	2 (12)	8 (13)	
CA125 concentration at diagnosis					0.220
Median (IQR)	340 (68–737)	690 (242–2057)	245 (59–603)	288 (163–1032)	
Missing (<i>n</i>)	-	1 (6)	1 (6)	-	
CA125 concentration after treatment					0.826
Median (IQR)	13 (9 – 16)	12 (8 – 16)	11 (7 – 13)	12 (6 – 14)	
Missing (<i>n</i>)	4 (24)	3 (18)	4 (24)	2 (13)	
Debulking type					0.990
Primary	9 (53)	10 (59)	9 (53)	8 (50)	
Interval	7 (41)	6 (35)	8 (47)	7 (44)	
Other**	1 (6)	1 (6)		1 (6)	
Debulking outcome					0.910
Complete	13 (76)	11 (65)	13 (76)	11 (69)	
Optimal	3 (18)	4 (23)	2 (12)	2 (12)	
Incomplete	1 (6)	2 (12)	2 (12)	3 (19)	

* Differences in continuous variables were tested with a Mann-Whitney U test (skewed distribution). For categorical variables, P-values were obtained from a

Fisher's exact test.

** Incomplete primary debulking followed by neo-adjuvant chemotherapy and afterwards a secondary interval debulking with adjuvant chemotherapy.

Abbreviations: IQR, interquartile range.